Cytokinetics Company Profile (NASDAQ:CYTK)

About Cytokinetics (NASDAQ:CYTK)

Cytokinetics logoCytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CYTK
  • CUSIP: N/A
  • Web:
  • Market Cap: $631.16 million
  • Outstanding Shares: 45,083,000
Average Prices:
  • 50 Day Moving Avg: $13.94
  • 200 Day Moving Avg: $12.20
  • 52 Week Range: $7.75 - $17.20
  • Trailing P/E Ratio: 189.19
  • Foreward P/E Ratio: -8.70
  • P/E Growth: -0.35
Sales & Book Value:
  • Annual Revenue: $102.14 million
  • Price / Sales: 6.18
  • Book Value: $2.20 per share
  • Price / Book: 6.36
  • EBIDTA: $3.88 million
  • Net Margins: -1.70%
  • Return on Equity: -2.17%
  • Return on Assets: -1.14%
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 5.32%
  • Quick Ratio: 5.05%
  • Average Volume: 709,331 shs.
  • Beta: 1.79
  • Short Ratio: 7.13

Frequently Asked Questions for Cytokinetics (NASDAQ:CYTK)

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) released its earnings results on Thursday, February, 16th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.55. The firm earned $33.14 million during the quarter, compared to analysts' expectations of $14.10 million. Cytokinetics had a negative return on equity of 2.17% and a negative net margin of 1.70%. View Cytokinetics' Earnings History.

Where is Cytokinetics' stock going? Where will Cytokinetics' stock price be in 2017?

9 brokers have issued twelve-month price objectives for Cytokinetics' shares. Their forecasts range from $15.00 to $25.00. On average, they expect Cytokinetics' stock price to reach $21.11 in the next twelve months. View Analyst Ratings for Cytokinetics.

What are analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:

  • 1. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (5/4/2017)
  • 2. Rodman & Renshaw analysts commented, "Our price target is based on our clinical net present value (NPV) model, which is currently driven by omecamtiv mecarbil ($19.77/share) and modest contributions from tirasemtiv ($4.26/share) and CK-107 ($1.05/share). We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (3/23/2017)
  • 3. HC Wainwright analysts commented, "We have adjusted our 2017 estimates downward accordingly. The company had a net loss of $4.3M in 4Q16, or ($0.81) per share based on shares adjusted for the 1-for-10 reverse split effective on February 27. 2016. The loss was lower than our estimate of $4.9M due to improved expense management. For the fiscal year 2016, TearLab had $28M in revenue, representing 11% growth over that of 2015, and $19.9M in net loss. In our view, the softened growth rate in the Flex program and in international markets could continue in 2017. Therefore, we currently project a conservative low single-digit growth in revenue in 2017. Our valuation of the company has decreased from $140M to $105M. Excluding debt, our estimated market value of the firm is $79M. Assuming 6.5M shares outstanding at the end of 2017, we project a 12-month price target of $12 per share. Our previous price target was $2 before the reverse split. Importantly, TearLab has begun a process to explore strategic alternatives, which does not preclude a sale of the company." (3/13/2017)
  • 4. Cantor Fitzgerald analysts commented, "We rate CYTK Overweight and maintain our $21 price target. Cytokinetics has three late-stage programs with quality partners that should begin to read data out in the next year. The company is targeting substantial unmet medical needs and has been methodically pursuing clinical development for its candidates. We think the major overhangs have receded from the shares and that, with near-term data on the horizon, the shares have opportunity for valuation expansion." (2/17/2017)
  • 5. FBR & Co analysts commented, "On February 16, CYTK announced 4Q16 results dominated by the achievement of significant milestones in its cardiac muscle-directed clinical program (omecamtiv mecarbil, or OM) and important milestones in its skeletal muscle program (tirasemtiv and CK-2127107), which we think will continue to emerge in value in 2017. One highlight was the initiation of the GALACTIC-HF Phase III outcomes trial with OM by its partner Amgen. Another 4Q highlight was enrollment of the first patient in the open-label VIGOR-ALS trial with tirasemtiv, designed to assess the safety of tirasemtiv, which would be directed for long-term daily use in patients with amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). We think CYTK's valuation is disconnected from the value of the more than $1B in milestone payments that CYTK could realize from its partners. Therefore, we reiterate our Outperform rating." (2/17/2017)

Are investors shorting Cytokinetics?

Cytokinetics saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 4,614,289 shares, an increase of 74.3% from the April 13th total of 2,646,959 shares. Based on an average daily trading volume, of 1,689,334 shares, the short-interest ratio is currently 2.7 days. Currently, 11.9% of the company's shares are sold short.

Who are some of Cytokinetics' key competitors?

Who owns Cytokinetics stock?

Cytokinetics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (13.60%), BIOTECHNOLOGY VALUE FUND L P (6.40%), Lansdowne Partners UK LLP (5.58%), Vanguard Group Inc. (4.69%), Wellington Management Group LLP (3.25%) and Acadian Asset Management LLC (0.80%). Company insiders that own Cytokinetics stock include Fady Ibraham Malik and L Patrick Gage. View Institutional Ownership Trends for Cytokinetics.

Who sold Cytokinetics stock? Who is selling Cytokinetics stock?

Cytokinetics' stock was sold by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., Wellington Management Group LLP, Goldman Sachs Group Inc., Keybank National Association OH, Bank of New York Mellon Corp, SG Americas Securities LLC, ProShare Advisors LLC and United Services Automobile Association. View Insider Buying and Selling for Cytokinetics.

Who bought Cytokinetics stock? Who is buying Cytokinetics stock?

Cytokinetics' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Acadian Asset Management LLC, Vanguard Group Inc., Bogle Investment Management L P DE, Oxford Asset Management, Russell Investments Group Ltd., Sphera Funds Management LTD. and TFS Capital LLC. View Insider Buying and Selling for Cytokinetics.

How do I buy Cytokinetics stock?

Shares of Cytokinetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cytokinetics stock cost?

One share of Cytokinetics stock can currently be purchased for approximately $14.00.

Analyst Ratings

Consensus Ratings for Cytokinetics (NASDAQ:CYTK) (?)
Ratings Breakdown: 8 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.11)
Consensus Price Target: $21.11 (50.79% upside)

Analysts' Ratings History for Cytokinetics (NASDAQ:CYTK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Cantor FitzgeraldReiterated RatingOverweightMediumView Rating Details
4/29/2017Cowen and CompanyReiterated RatingOutperform$17.00 -> $19.00LowView Rating Details
4/25/2017HC WainwrightReiterated RatingBuy$25.00LowView Rating Details
3/23/2017Rodman & RenshawReiterated RatingBuy$25.00MediumView Rating Details
2/17/2017FBR & CoReiterated RatingOutperform$24.00N/AView Rating Details
2/17/2017Needham & Company LLCReiterated RatingStrong-Buy$22.00N/AView Rating Details
2/17/2017Piper Jaffray CompaniesReiterated RatingOverweight$15.00N/AView Rating Details
12/1/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$22.00N/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$16.00 -> $14.00N/AView Rating Details
7/24/2015MLV & Co.Reiterated RatingBuy$9.00 -> $14.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Cytokinetics (NASDAQ:CYTK)
Earnings by Quarter for Cytokinetics (NASDAQ:CYTK)
Earnings History by Quarter for Cytokinetics (NASDAQ:CYTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/16/2017Q416($0.39)$0.16$14.10 million$33.14 millionViewListenView Earnings Details
10/27/2016Q3($0.27)$0.74$6.67 million$59.05 millionViewListenView Earnings Details
7/28/2016Q2($0.28)($0.29)$7.80 million$5.80 millionViewListenView Earnings Details
4/28/2016Q1($0.37)($0.31)$8.14 million$8.42 millionViewListenView Earnings Details
2/16/2016Q415($0.32)($0.24)$10.49 million$9.80 millionViewListenView Earnings Details
10/29/2015Q315($0.30)($0.23)$11.24 million$7.90 millionViewListenView Earnings Details
7/29/2015Q2($0.28)($0.27)$4.00 million$6.54 millionViewListenView Earnings Details
4/30/2015Q1($0.08)($0.23)$10.10 million$4.40 millionViewListenView Earnings Details
2/12/2015Q4($0.17)$0.23$10.80 million$21.80 millionViewListenView Earnings Details
10/30/2014Q3($0.27)($0.16)$6.50 million$9.42 millionViewListenView Earnings Details
7/30/2014Q2($0.32)($0.23)$7.01 million$7.80 millionViewListenView Earnings Details
5/6/2014Q1($0.34)($0.27)$7.69 million$8.00 millionViewListenView Earnings Details
2/6/2014Q4($0.08)$0.21$19.14 million$24.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cytokinetics (NASDAQ:CYTK)
2017 EPS Consensus Estimate: ($2.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.66)($0.66)($0.66)
Q3 20171($0.70)($0.70)($0.70)
Q4 20171($0.75)($0.75)($0.75)
(Data provided by Zacks Investment Research)


Dividend History for Cytokinetics (NASDAQ:CYTK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cytokinetics (NASDAQ:CYTK)
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 66.09%
Insider Trades by Quarter for Cytokinetics (NASDAQ:CYTK)
Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)
Insider Trades by Quarter for Cytokinetics (NASDAQ:CYTK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/29/2016Fady Ibraham MalikEVPSell5,633$12.36$69,623.88View SEC Filing  
8/31/2015L Patrick GageDirectorBuy1,000$6.95$6,950.00View SEC Filing  
8/20/2015L Patrick GageDirectorBuy10,000$6.55$65,500.00View SEC Filing  
5/6/2015L Patrick GageDirectorBuy10,000$5.71$57,100.00View SEC Filing  
3/11/2015Andrew A WolffCMOSell21,875$7.80$170,625.00View SEC Filing  
12/30/2014Fady Ibraham MalikSVPSell21,630$6.73$145,569.90View SEC Filing  
5/9/2014L Patrick GageDirectorBuy10,850$4.09$44,376.50View SEC Filing  
2/25/2014Eastern Capital Ltdmajor shareholderBuy500,000$8.00$4,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cytokinetics (NASDAQ:CYTK)
Latest Headlines for Cytokinetics (NASDAQ:CYTK)
DateHeadline logoCytokinetics, Inc. (CYTK) Earns "Overweight" Rating from Cantor Fitzgerald - May 23 at 7:12 AM logoCytokinetics, Inc. (CYTK) Given Average Rating of "Buy" by Brokerages - May 22 at 12:24 PM logo Analysts Expect Cytokinetics, Inc. (CYTK) to Post -$0.68 EPS - May 15 at 2:22 PM logoCytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular Atrophy - May 15 at 11:54 AM logoShort Interest in Cytokinetics, Inc. (CYTK) Increases By 74.3% - May 11 at 8:36 AM logoCytokinetics Announces Proposed Public Offering of Common Stock - May 9 at 5:25 AM logoCytokinetics Announces Pricing of Public Offering of Common Stock - May 9 at 5:25 AM logoCytokinetics, Inc. (CYTK) Cut to "Strong Sell" at Zacks Investment Research - May 4 at 9:49 PM logoCytokinetics (CYTK) Earns News Sentiment Rating of -0.19 - May 4 at 10:43 AM logoCytokinetics, Inc. (CYTK) to Post Q2 2017 Earnings of ($0.66) Per Share, FBR & Co Forecasts - May 4 at 9:19 AM logoCytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS - May 3 at 4:34 PM logoCytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS - May 3 at 4:34 PM logoCytokinetics (CYTK) Given Daily News Impact Score of 0.05 - May 1 at 6:30 PM logoCytokinetics Announces Results from Dose Escalation Phase of COSMIC-HF Presented at Heart Failure 2017 - May 1 at 8:13 AM logoFBR & Co Comments on Cytokinetics, Inc.'s Q1 2017 Earnings (CYTK) - May 1 at 7:09 AM logoCytokinetics' (CYTK) "Outperform" Rating Reiterated at Cowen and Company - April 29 at 8:02 PM logoSomewhat Favorable News Coverage Likely to Affect Cytokinetics (CYTK) Share Price - April 28 at 11:36 PM logoEdited Transcript of CYTK earnings conference call or presentation 27-Apr-17 8:30pm GMT - April 28 at 5:41 PM logoCytokinetics reports 1Q loss - April 28 at 5:41 PM logoCytokinetics, Inc. Reports First Quarter 2017 Financial Results - GlobeNewswire (press release) - April 27 at 5:10 PM logoCytokinetics, Inc. Reports First Quarter 2017 Financial Results - April 27 at 5:10 PM logoSomewhat Favorable Media Coverage Likely to Impact Cytokinetics (CYTK) Stock Price - April 25 at 7:28 PM logoCytokinetics, Inc. (CYTK) Given a $25.00 Price Target by HC Wainwright Analysts - April 25 at 5:04 PM logoCytokinetics, Inc. (CYTK) Receives Average Rating of "Buy" from Brokerages - April 25 at 12:33 PM logoCytokinetics, Inc. (CYTK) Expected to Announce Earnings of -$0.11 Per Share - April 24 at 9:20 PM logoETFs with exposure to Cytokinetics, Inc. : April 24, 2017 - April 24 at 4:31 PM logoCytokinetics (CYTK) Earns Daily Media Impact Rating of 0.12 - April 22 at 11:15 AM logoCytokinetics: Stretching For The Winner's Circle - April 21 at 4:42 PM logoCytokinetics Added to S&P SmallCap 600 - April 21 at 4:42 PM logoCytokinetics, Inc. – Value Analysis (NASDAQ:CYTK) : April 20, 2017 - April 20 at 4:47 PM logoCytokinetics, Inc.: Leads amongst peers with strong fundamentals - April 19 at 4:37 PM logoCytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : April 19, 2017 - April 19 at 12:34 PM logoWhy Cytokinetics, Inc. Jumped Higher Today - April 18 at 1:31 PM logoFavorable Media Coverage Likely to Impact Cytokinetics (CYTK) Stock Price - April 13 at 6:35 PM logoCytokinetics to Announce First Quarter Results on April 27, 2017 - GlobeNewswire (press release) - April 13 at 4:39 PM logoCytokinetics to Announce First Quarter Results on April 27, 2017 - April 13 at 4:39 PM logoCytokinetics, Inc. breached its 50 day moving average in a Bearish Manner : CYTK-US : April 6, 2017 - April 7 at 9:21 AM logoCytokinetics, Inc. (CYTK) Receives Average Rating of "Buy" from Analysts - March 31 at 1:22 PM logoCytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy - March 29 at 11:57 AM logoCytokinetics (CYTK), Origent Data Sciences Announce Advancement of Collaboration in ALS - - March 25 at 9:39 PM logoCK-107 - March 25 at 11:01 AM logo7 Analyst Stock Picks That Could Surge 50%, 100% or Exponentially - March 25 at 11:01 AM logoCytokinetics Still A Buy After Phase 2 SMA Data - March 23 at 10:12 PM logoCytokinetics (CYTK), Origent Data Sciences Announce Advancement of Collaboration in ALS - March 23 at 5:11 PM logoOrigent Data Sciences and Cytokinetics Advance Collaboration Intended to Validate Predictive Analytics Model in ALS - March 23 at 5:11 PM logoCytokinetics, Inc. (CYTK) Given Buy Rating at Rodman & Renshaw - March 23 at 3:55 PM logoCytokinetics (CYTK) Reports Preclinical Data for CK-2127107 ... - - March 23 at 2:48 AM logoCytokinetics SMA Drug Did Well in Early Study (CYTK) - March 22 at 4:46 PM logoCytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference - March 22 at 4:46 PM logoCytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17 - March 20 at 7:54 PM



Cytokinetics (CYTK) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff